Literature DB >> 27797804

Everolimus-associated stomatitis in a patient who had renal transplant.

Yisi D Ji1, Ali Aboalela2, Alessandro Villa3.   

Abstract

Everolimus is used as an immunosuppressant in renal allograft transplant rejection and in metastatic breast cancer treatment. One side effect of everolimus is stomatitis, referred to as mammalian target of rapamycin inhibitor-associated stomatitis. This side effect can affect treatment course and contribute to discontinuation of therapy or dose reduction, previously reported in the treatment of metastatic breast cancer. Here, we present a case of everolimus-associated stomatitis with a novel management method with intralesional triamcinolone that allows for continuous course of everolimus. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27797804      PMCID: PMC5073606          DOI: 10.1136/bcr-2016-217513

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  21 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus.

Authors:  Rapur Ram; Gudithi Swarnalatha; Prasad Neela; Kaligotla Venkata Dakshinamurty
Journal:  Saudi J Kidney Dis Transpl       Date:  2008-09

Review 3.  Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.

Authors:  Joachim Andrassy; Verena S Hoffmann; Markus Rentsch; Manfred Stangl; Antje Habicht; Bruno Meiser; Michael Fischereder; Karl-Walter Jauch; Markus Guba
Journal:  Transplantation       Date:  2012-12-27       Impact factor: 4.939

Review 4.  Everolimus in liver transplantation.

Authors:  James F Trotter; Luis Lizardo-Sanchez
Journal:  Curr Opin Organ Transplant       Date:  2014-12       Impact factor: 2.640

Review 5.  Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments.

Authors:  Hans-Hellmut Neumayer
Journal:  Transplantation       Date:  2005-05-15       Impact factor: 4.939

6.  mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus.

Authors:  Eleni-Marina Kalogirou; Konstantinos I Tosios; Evangelia P Piperi; Alexandra Sklavounou
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2014-09-16

7.  Clinical presentation and management of mTOR inhibitor-associated stomatitis.

Authors:  Marcio Augusto de Oliveira; Fabiana Martins E Martins; Qian Wang; Stephen Sonis; George Demetri; Suzanne George; James Butrynski; Nathaniel S Treister
Journal:  Oral Oncol       Date:  2011-09-03       Impact factor: 5.337

Review 8.  Mammalian target of rapamycin inhibitor-associated stomatitis.

Authors:  Christine B Boers-Doets; Judith E Raber-Durlacher; Nathaniel S Treister; Joel B Epstein; Anniek B P Arends; Diede R Wiersma; Rajesh V Lalla; Richard M Logan; Nielka P van Erp; Hans Gelderblom
Journal:  Future Oncol       Date:  2013-12       Impact factor: 3.404

9.  Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.

Authors:  J Radtke; N Dietze; V N Spetzler; L Fischer; E-G Achilles; J Li; S Scheidat; F Thaiss; B Nashan; M Koch
Journal:  Transpl Infect Dis       Date:  2016-02-03       Impact factor: 2.228

Review 10.  Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.

Authors:  Douglas E Peterson; Joyce A O'Shaughnessy; Hope S Rugo; Sharon Elad; Mark M Schubert; Chi T Viet; Cynthia Campbell-Baird; Jan Hronek; Virginia Seery; Josephine Divers; John Glaspy; Brian L Schmidt; Timothy F Meiller
Journal:  Cancer Med       Date:  2016-06-23       Impact factor: 4.452

View more
  3 in total

1.  Oral administration of salmon cartilage proteoglycan extends the survival of allografts in mice.

Authors:  Krisana Asano; Emiko Takahashi; Sayuri Yoshimura; Akio Nakane
Journal:  Biomed Rep       Date:  2017-11-02

Review 2.  Use of everolimus in liver transplantation.

Authors:  Mei-Ling Yee; Hui-Hui Tan
Journal:  World J Hepatol       Date:  2017-08-18

3.  Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients.

Authors:  Claudia Arena; Giuseppe Troiano; Khrystyna Zhurakivska; Riccardo Nocini; Lorenzo Lo Muzio
Journal:  Onco Targets Ther       Date:  2019-11-14       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.